Targeted Therapy With Enasidenib for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
Blood Adv 2022 Aug 16;[EPub Ahead of Print], CD DiNardo, S Venugopal, CA Lachowiez, K Takahashi, S Loghavi, G Montalban-Bravo, X Wang, HE Carraway, MA Sekeres, A Sukkur, D Hammond, KS Chien, A Maiti, L Masarova, K Sasaki, Y Alvarado, TM Kadia, NJ Short, NG Daver, G Borthakur, F Ravandi, HM Kantarjian, BJ Patel, AE DeZern, GJ Roboz, G Garcia-ManeroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.